Associated tags: PD-L1, IDO, Pharmaceutical industry, Vaccine, IO, Patient, Monmouthshire, Pembrolizumab, Cancer
Locations: UNITED KINGDOM, MARYLAND, US, BOSTON, MA, SOUTH AFRICA, NEW YORK, NY, UNITED STATES, DENMARK
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY.
Key Points:
- NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY.
- A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.
Retrieved on:
Wednesday, April 24, 2024
Cancer,
SCCHN,
Lung cancer,
Neck,
Vaccine,
PD-1,
ASCO,
Patient,
Society,
Melanoma,
Head,
Annual general meeting,
Pharmaceutical industry NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.
Key Points:
- NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.
- A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in the perioperative setting in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) will be presented.
- “We are committed to investigating the use of IO102-IO103 combined with PD-1 inhibitors to treat various types of cancer, including melanoma, lung cancer and head and neck cancer,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
- “The IOB-032 Phase 2 study is designed to provide us with insights into treatment outcomes in earlier disease settings with neoadjuvant and adjuvant treatment of patients with melanoma and SCCHN and we look forward to the results of this trial.”
University,
Cancer,
Commercial,
Kite Pharma,
Jazz Pharmaceuticals,
Vaccine,
Therapy,
SVP,
Patient,
Doctor of Pharmacy,
IO,
Trade,
Amgen,
Pharmaceutical industry Ms. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States.
Key Points:
- Ms. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States.
- “Marjan’s extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercial readiness phase for IO102-IO103,” said Dr. Zocca.
- “We’re thrilled to welcome Marjan to the IO Biotech team as we continue to expand our pipeline with product candidates in multiple cancer indications where the T-Win platform may prove highly effective.”
Dr. Shamsaei added, “It is an honor to join IO Biotech’s team during this exciting growth phase in the company.
- Prior to this role, she served in leadership roles at Five Prime Therapeutics (acquired by Amgen), Genentech, Jazz Pharmaceuticals and SUGEN/Pharmacia (acquired by Pfizer).
TME,
Cell,
Environment,
Immunosuppression,
IDO1,
Tumor microenvironment,
AACR,
Neoplasm,
Vaccination,
Poster,
Vaccine,
Pharmaceutical industry NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
Key Points:
- NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
- “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
- Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions.
- The poster can be found on the “ Posters & Publications ” page of the IO Biotech website and on the AACR website.
External,
Medical biology,
IO,
Employment,
Survival,
Pfizer,
Business development,
Cancer,
Engineering,
Doctor of Philosophy,
Eli Lilly and Company,
Kadmon Corporation,
Vaccine,
Lead,
Pharmaceutical industry NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.
Key Points:
- NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.
- Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships.
- Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately.
- “We are very excited to welcome Faiçal to IO Biotech,” said Dr. Zocca.
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
Key Points:
- NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
- The poster will include nonclinical data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.
- “We are excited with our new nonclinical data clearly demonstrating how the dual antigen vaccine IO102-IO103 differentially contribute to the anti-tumor effect: while IO102 treatment results in the reduction of the immune suppression in the TME, IO103 appears to impact by enhancement of T effector function,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
- “These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively.”
NSCLC,
Lung cancer,
PFS,
Research,
ESMO,
BCG,
MD,
SCCHN,
SITC,
Pembrolizumab,
Vaccine,
Annual general meeting,
Society,
Conference,
Patient,
Acceleration,
Survival,
Immunotherapy,
Oncology,
WCLC,
Pharmaceutical industry “In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
Key Points:
- “In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
- The company expanded its Board of Directors with the appointment of Helen Collins, MD in November 2023.
- Cash and cash equivalents as of December 31, 2023 were $143.2 million, compared to $142.6 million at December 31, 2022.
- During the three months ended December 31, 2023, the company used cash, cash equivalents and restricted cash of $22.9 million from operating and investing activities.
Retrieved on:
Monday, February 26, 2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the 44th Annual Cowen Health Care Conference to be held March 4-6, 2024 in Boston, MA.
Key Points:
- NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the 44th Annual Cowen Health Care Conference to be held March 4-6, 2024 in Boston, MA.
- A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.
Retrieved on:
Thursday, December 21, 2023
Research,
PD-1,
SCCHN,
Vaccine,
Lung cancer,
Disease,
Melanoma,
MD,
Doctor of Philosophy,
Clinical trial,
Cancer,
Head,
Patient,
Neck,
Pharmaceutical industry “In patients with advanced melanoma, the activity and tolerability profile of IO102-IO103 and a PD-1 inhibitor has been demonstrated in the Phase 1/2 trial and we are now conducting a pivotal Phase 3 trial in patients with advanced melanoma, with enrollment completed in that study and an interim analysis planned in 2024.
Key Points:
- “In patients with advanced melanoma, the activity and tolerability profile of IO102-IO103 and a PD-1 inhibitor has been demonstrated in the Phase 1/2 trial and we are now conducting a pivotal Phase 3 trial in patients with advanced melanoma, with enrollment completed in that study and an interim analysis planned in 2024.
- Dosing the first patient in this trial demonstrates our commitment to further explore the potential our therapeutic cancer vaccine may offer to a broader group of patients with cancer.
- Leading global experts from centers of excellence in this field in the US, Australia and Europe are involved in this clinical trial.
- We look forward to following the progress of this study.”
Retrieved on:
Monday, November 13, 2023
SCCHN,
Neck,
Research,
Annual general meeting,
Therapy,
Head,
CFO,
Amgen,
ESMO,
Patient,
IDO1,
PFS,
Vaccine,
Pembrolizumab,
Immunotherapy,
Conference,
ORR,
Melanoma,
MD,
SITC,
Lung cancer,
Doctor of Philosophy,
Congress,
Neoplasm,
Society,
WCLC,
Pharmaceutical industry,
Cryptocurrency “Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.
Key Points:
- “Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.
- Encouraging preliminary data from this basket trial were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the ESMO Congress in October 2023.
- General and administrative expenses were consistent at $5.8 million for the three months ended September 30, 2023 and 2022, respectively.
- Cash and cash equivalents as of September 30, 2023, were $165.5 million, compared to $142.6 million at December 31, 2022.
